Candida auris, a drug-resistant fungus that the Centers for Disease Control and Prevention first flagged to U.S. healthcare facilities in June 2016, has now spread to 27 states and carries crude mortality rates reaching up to half of hospitalized patients. Clinical cases rose at a steep rate during 2020 and 2021, driven by sustained transmission inside hospitals and long-term care settings. The organism has proven capable of resisting all three major classes of antifungal medications, leaving doctors with few treatment options for the sickest patients.
Why C. auris spread accelerated during the pandemic years
The CDC’s initial clinical alert in 2016 warned that C. auris was an emerging multidrug-resistant yeast requiring immediate laboratory identification and infection-control measures. Within a year, a CDC field report documented that the organism had shifted from isolated importations to ongoing healthcare-associated transmission across multiple facilities. That early warning, however, did not prevent the fungus from gaining a permanent foothold in the U.S. healthcare system.
The sharpest acceleration came during the COVID-19 pandemic. A peer-reviewed analysis published in the Annals of Internal Medicine found that C. auris spread across multiple U.S. states between 2019 and 2021, with case counts climbing far beyond pre-pandemic levels. Overburdened infection-control programs, stretched staffing, and heavy use of personal protective equipment all created conditions favorable to the fungus, which persists on surfaces and medical devices for weeks.
A related but less examined factor is antifungal prescribing pressure. Echinocandins, the primary drug class used against C. auris, saw increased use during COVID-19 surges as critically ill patients developed secondary fungal infections. That prescribing pattern may have created selective pressure favoring resistant strains, though no published study has yet directly linked state-level antifungal usage data to resistance patterns captured by the CDC’s Antimicrobial Resistance Laboratory Network. The hypothesis is testable with existing datasets, but the analysis has not appeared in the peer-reviewed literature as of early 2026.
Pan-resistant strains and mortality data from CDC surveillance
The most alarming development in the C. auris timeline came when investigators identified isolates in New York in 2019 that were resistant to all three major antifungal classes: azoles, polyenes, and echinocandins. These pan-resistant strains left clinicians with essentially no reliable pharmacological options, a situation rarely seen with other fungal pathogens. The New York investigation triggered public-health responses at both the state and federal level, but the strains had already circulated within healthcare networks.
Hospitalization outcomes paint a grim picture. A CDC analysis of C. auris-associated hospitalizations from 2017 through 2022, published in the journal Emerging Infectious Diseases, found that crude mortality was high across the cohort and even higher among patients with bloodstream infections. Those bloodstream cases represent the most invasive form of C. auris disease and carry the steepest fatality rates, supporting the claim that the fungus kills up to half of those it infects under certain clinical conditions.
The AR Lab Network continued testing U.S. isolates through 2022 and 2023, classifying resistance profiles and defining how echinocandin resistance and pan-resistance are assessed. Recent CDC-authored genomic epidemiology has mapped U.S. lineages and identified specific resistance mechanisms, including mutations in the FKS1 gene region. Whole-genome sequencing now supports outbreak detection and helps trace how clusters move between facilities, but the network’s capacity to keep pace with the fungus depends on sustained federal funding and laboratory staffing that have faced pressure in recent budget cycles.
Gaps in tracking and what patients should watch for
Several questions remain unanswered despite nearly a decade of U.S. surveillance. Exact state-by-state clinical case counts for the most recent years have not been fully published in the CDC’s primary tracking dashboard, making it difficult for researchers and the public to assess how quickly the fungus is still spreading. Patient-level risk factors and outcomes beyond crude mortality, such as length of stay, underlying conditions, and treatment regimens, are absent from the 2017 to 2022 hospitalization analysis.
Direct statements from senior federal health officials on a national containment strategy have been limited. The CDC framed C. auris as an urgent antimicrobial-resistance threat in its March 2023 press communication, but no standalone containment plan with measurable benchmarks has been issued. Real-time facility-level transmission data after 2021 remain unavailable outside aggregated laboratory network summaries, which means individual hospitals and nursing homes cannot easily benchmark their own risk against national trends.
For patients and families, the practical takeaway is specific. Anyone entering a hospital or long-term care facility should feel empowered to ask basic infection-prevention questions: how often high-touch surfaces are disinfected, whether shared equipment such as blood pressure cuffs and thermometers are cleaned between uses, and whether the facility has recently managed C. auris cases. While patients cannot see the organism, they can observe whether staff follow hand hygiene protocols before touching them or their devices.
Patients with central venous catheters, urinary catheters, tracheostomies, or other invasive devices face higher risk for severe fungal infections in general. Families can ask clinicians whether each device is still medically necessary and how often it is being evaluated for removal. Reducing unnecessary device days lowers the opportunities for C. auris to enter the bloodstream or other normally sterile body sites.
People transferred between facilities, especially from long-term acute-care hospitals or skilled-nursing facilities, should make sure their receiving providers know their recent care history. C. auris often spreads silently through patient transfers, and complete handoffs can prompt screening or isolation precautions when appropriate. Patients can carry the organism on their skin without symptoms, so a lack of obvious infection does not rule out colonization.
At the policy level, experts argue that more transparent and timely data would help both clinicians and the public understand the evolving threat. Publishing standardized, lagged-but-regular updates on state-level case counts, resistance patterns, and outbreak investigations could guide resource allocation and support targeted infection-prevention training. Integrating C. auris metrics into broader antimicrobial-resistance dashboards would also make it easier to track whether control measures are working.
Until those gaps are closed, C. auris will remain a largely invisible problem to most Americans, even as it continues to challenge infection-control teams inside hospitals and nursing homes. The fungus exploits weaknesses in healthcare systems-overcrowded wards, staffing shortages, gaps in cleaning and disinfection-that became more pronounced during the pandemic years. Addressing those systemic vulnerabilities will protect patients not only from C. auris, but from the next multidrug-resistant organism waiting in the wings.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
